Testosterone Gel Monotherapy Improves Sexual Function of Hypogonadal Men Mainly Through Restoring Erection: Evaluation by IIEF Score

Chiang, Han-Sun; Cho, Shu-Ling; Lin, Yi‐Chia; Hwang, Thomas I. S.

doi:10.1016/j.urology.2008.10.019

Cited by 47 publications

(40 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies with testosterone have had conflicting results iconcerning this topic. Some studies have corroborated our findings, such as the one recently conducted in Taiwan, where IIEF was applied before and after testosterone replacement in 20 males proven to be hypogonadal and who showed an improvement in sexual dysfunction evidenced by improved erection (25). Many studies showed a short-term improvement in the erectile dysfunction, and some authors reported an improvement of approximately 50% in sexual potency and libido (26), also observed by our group.…”

Section: Discussionsupporting

confidence: 89%

Short term testosterone replacement therapy improves libido and body composition

Júnior¹,

Clapauch²,

Buksman

2009

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objective: To assess the efficacy and safety of testosterone replacement in males with late-onset hypogonadism compared to hypogonadal men without replacement, and controls, during six months. Methods: We assessed, through ADAM, AMS, IIEF-5 and SF-36 questionnaires, and through clinical and laboratorial examinations, 62 patients divided into three groups: 17 hypogonadal males (HR) used intramuscular testosterone every three weeks; 14 hypogonadal males (HV) and 31 non-hypogonadal males (CV) used oral vitamins daily. Results: When compared to others, HR group obtained libido improvement assessed by ADAM 1 (p = 0.004), and borderline sexual potency improvement assessed by IIEF-5 (p = 0.053), besides a decrease in waist circumference after eight weeks (p = 0.018). The remaining parameters did not differ between the groups. PSA and hematocrit remained stable in those using testosterone. Conclusion: Six months of testosterone replacement improved sexuality and body composition, with prostatic and hematological safety. KeywordsTestosterone replacement therapy; late onset hypogonadism; andropause; libido; body composition; waist circumference resumo Objetivo: Avaliar a eficácia e a segurança da reposição de testosterona em homens com hipogonadismo tardio comparados a hipogonádicos sem reposição e controles, durante seis meses. Métodos: Mediante os questionários ADAM, AMS, IIEF-5 e SF-36, foram feitos exame clínico e laboratorial em 62 pacientes divididos em três grupos: 17 hipogonádicos (HR) usaram testosterona intramuscular a cada três semanas; 14 hipogonádicos (HV) e 31 não hipogonádi-cos (CV) usaram vitaminas via oral diariamente. Resultados: Comparado aos demais, o grupo HR obteve melhora da libido avaliada pelo ADAM 1 (p = 0,004) e melhora limítrofe da potência sexual avaliada pelo IIEF-5 (p = 0.053), além de diminuição da cintura a partir da oitava semana (p = 0,018). Os demais parâmetros não foram diferentes entre os grupos. PSA e hematócrito se mantiveram estáveis nos que usaram testosterona. Conclusão: A reposição de testosterona durante seis meses melhorou a sexualidade e a composição corporal, com segurança prostática e hematológica. Arq Bras Endocrinol Metab. 2009;53(8):996-1004 Descritores

show abstract

Section: Discussionsupporting

confidence: 89%

Short term testosterone replacement therapy improves libido and body composition

Júnior¹,

Clapauch²,

Buksman

2009

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Recent work has established a role for testosterone in the development and maintenance of erections, and testosterone replacement has been shown to ameliorate the symptoms of LOH, including erectile dysfunction. [33][34][35] In contrast, the role of GH in the maintenance of sexual function is less well established, although studies have shown a relationship between GH and erectile function.…”

Section: Discussionmentioning

confidence: 99%

IGF-1 levels are significantly correlated with patient-reported measures of sexual function

et al. 2011

View full text Add to dashboard Cite

Growth hormone (GH) supplementation may help to preserve erectile function. We assessed whether serum insulin-like growth factor 1 (IGF-1) levels, a surrogate for GH levels, correlate with sexual function scores in 65 men who completed the Sexual Health Inventory for Men (SHIM) and Expanded Prostate Cancer Index Composite (EPIC) questionnaires, and had serum IGF-1 and testosterone levels determined. Median±s.d. IGF-1 level, SHIM and EPIC scores were 235.0±86.4, 19.5 ± 8.7 and 56.4 ± 28.3 mg ml À1 , respectively. IGF-1 levels and total SHIM score correlate significantly (r ¼ 0.31, P ¼ 0.02), as do IGF-1 levels and all individual SHIM question scores, and IGF-1 levels and the sexual domain of the EPIC questionnaire (r ¼ 0.30, P ¼ 0.02). No correlation was observed between IGF-1 levels and Gleason score, IGF-1 and testosterone level or SHIM score and testosterone level. These data support a potential role for the GH axis in erectile function.

show abstract

“…Bu nedenle transdermal testosteron preperatları tercih edilebilmektedir (19). Bizim hastalarımızda da androjen replasmanı amacı ile daha önce literatürde tanımlandığı şekilde transdermal testosteron tedavisi kullanılmıştır (20).…”

Section: Gereç Ve Yöntemlerunclassified

Efficacy of androgen replacement therapy in patients with coexistence of hipogonadism and venoocclusive erectile dysfunction

Öztürk¹,

Şener²,

Göktuğ³

et al. 2013

Gaziantep Med J

View full text Add to dashboard Cite

ÖzetSerum testosteron seviyelerinde azalma güçsüzlük, halsizlik, depresif ruh hali gibi sistemik belirtilerin yanı sıra libidoda azalma, erektil disfonksiyon (ED) gibi seksüel belirti ve bulgulara da yol açabilmektedir. Düşük testosteron seviyesi korporal veno-okluziv mekanizmada da bozukluğa yol açabilmektedir. Çalışmamızda venöz yetmezlik, ED ve hipogonadizm birlikteliği olan olgularda testosteron replasman tedavisi ile venöz yetmezliğin tedavi edilebileceğini göstermeyi amaçladık. Çalışma Ocak 2009-Mart 2012 tarihleri arasında ED yakınması ile kliniğimize başvuran 500 hastanın dosya kayıtları incelenerek retrospektif olarak gerçekleştirildi. ED sebebi olabilecek diğer nedenler ekarte edilerek hipogonadizm ve venöz yetmezlik tespit edilmiş ve en az 6 ay androjen replasman tedavisi uygulanmış 37 hasta çalışmaya alındı. Tüm olgular IIEF-5 (International Index of Erectile Disfuncion) skoru, serum testosteron ölçümleri ve penil renkli Doppler Ultrasonografi (PRDUS) ile değerlendirildi. Altı aylık tedavi sonrası hastaların IIEF-5 skorları ve testosteron ölçümleri tekrarlanarak ve tedavi öncesi değerlerle istatistiksel olarak karşılaştırılarak androjen replasman tedavisinin faydalı olup olmadığı araştırıldı. Hastaların tamamının testosteron yerine koyma tedavisi ile fizyolojik seviyelerde testosteron değerlerine ulaştığı tespit edildi. Tedavi sonunda total ve serbest testosteron seviyelerinde istatistiksel olarak anlamlı artış saptanırken hemoglobin ve PSA değerlerinde değişim izlenmedi. Hastaların ortalama IIEF skorlarında da artma 37 hastanın 29'unda (%78) saptandı. Hiçbir hastada androjen replasman tedavisine bağlı herhangi bir yan etki olmadığı görüldü. ED hastalarında hipogonadizm ve hipogonadizm bağımlı venöz yetmezliğin de mutlaka akla getirilmesi ve testosteron replasmanı ile büyük ölçüde tedavi edilebileceği inancındayız. Anahtar kelimeler: Erektil disfonksiyon; hipogonadizm; testosteron. AbstractDecreases in plasma testosterone levels cause not only fatigue, depression, but also sexual symptoms such as decrease in libido or erectile dysfunction (ED). Low testosterone levels can cause venoocclusive dysfunction. In this study, we aimed to show that ED could be treated by testosterone replacement in patients with venoocclusive dysfunction and hipogonadism. Data of 500 patients applied to our clinic with ED between January 2009-March 2012 were examined retrospectively for coexistence of erectile dysfunction, hipogonadism and venoocclusive dysfunction. International Index of Erectile Disfuncion (IIEF-5) scores and plasma testosterone levels of the patients were evaluated. Venoocclusive dysfunction was determined by penile color Doppler ultrasound. After excluding other causes that can cause ED, 37 patients administered testosterone replacement therapy for hipogonadism and venoocclusive erectile dysfunction, were enrolled in the study. After 6 months, IIEF-5 scores and plasma testosterone levels of the patients were reevaluated. After treatment, 29 of 37 patients (78%) were found to improve for ED. Patients with...

show abstract

Testosterone Gel Monotherapy Improves Sexual Function of Hypogonadal Men Mainly Through Restoring Erection: Evaluation by IIEF Score

Cited by 47 publications

References 26 publications

Short term testosterone replacement therapy improves libido and body composition

Short term testosterone replacement therapy improves libido and body composition

IGF-1 levels are significantly correlated with patient-reported measures of sexual function

Efficacy of androgen replacement therapy in patients with coexistence of hipogonadism and venoocclusive erectile dysfunction

Contact Info

Product

Resources

About